Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est

Benzinga Newsdesk www.benzinga.com Negative 59.9%

Neg 59.9% Neu 0% Pos 0%

Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.